BACKGROUND The heart failure patient population can be challenging to treat and monitor. This is especially true when they travel to high altitudes where changes in pressure can affect their clinical status. The CardioMEMS™ HF System (Abbott Cardiovascular, Abbott Park, IL, USA) is an implanted miniature wireless device located in the pulmonary artery that transmits data on pulmonary artery pressure and heart rate. This data can be used to detect this dramatic invasive pressure change. CASE REPORT We present the case of a 78-year-old man with an exacerbation of heart failure while traveling to high altitude. Elevation of his pulmonary artery (PA) pressures were detected by his implanted CardioMEMS device. Understanding the expected change in PA pressure recordings helped to identify a true exacerbation of heart failure in our patient. This led to a prompt change in medical therapy, which ultimately prevented hospitalization. CONCLUSIONS Increased elevation can lead to falsely elevated PA pressure readings by the CardioMEMS device. However, we present the case of a patient with a disproportionate elevation of his hemodynamic pressure measurements, indicating an exacerbation of heart failure. This case demonstrates the value of the CardioMEMS device in detecting PA pressure changes in these unique circumstances.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520869PMC
http://dx.doi.org/10.12659/AJCR.922857DOI Listing

Publication Analysis

Top Keywords

heart failure
20
pulmonary artery
12
exacerbation heart
12
cardiomems device
12
high altitude
8
cardiomems™ system
8
failure patient
8
pressure
7
heart
6
failure
5

Similar Publications

Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults.

Drugs Aging

January 2025

Program for the Care and Study of the Aging Heart, Department of Medicine, Weill Cornell Medicine, 420 East 70th St, New York, NY, LH-36510063, USA.

There are several pharmacologic agents that have been touted as guideline-directed medical therapy for heart failure with preserved ejection fraction (HFpEF). However, it is important to recognize that older adults with HFpEF also contend with an increased risk for adverse effects from medications due to age-related changes in pharmacokinetics and pharmacodynamics of medications, as well as the concurrence of geriatric conditions such as polypharmacy and frailty. With this review, we discuss the underlying evidence for the benefits of various treatments in HFpEF and incorporate key considerations for older adults, a subpopulation that may be at higher risk for adverse drug events.

View Article and Find Full Text PDF

Novel Therapies for Right Ventricular Failure.

Curr Cardiol Rep

January 2025

Pediatric Advanced Heart Failure and Heart Transplant Program, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, USA.

Purpose Of Review: Traditionally viewed as a passive player in circulation, the right ventricle (RV) has become a pivotal force in hemodynamics. RV failure (RVF) is a recognized complication of primary cardiac and pulmonary vascular disorders and is associated with a poor prognosis. Unlike treatments for left ventricular failure (LVF), strategies such as adrenoceptor signaling inhibition and renin-angiotensin system modulation have shown limited success in RVF.

View Article and Find Full Text PDF

Recent evidence suggests that ketone bodies have therapeutic potential in many cardiovascular diseases including heart failure (HF). Accordingly, this has led to multiple clinical trials that use ketone esters to treat HF patients, which we term ketone therapy. Ketone esters, specifically ketone monoesters, are synthetic compounds which, when consumed, are de-esterified into two β-hydroxybutyrate (βOHB) molecules and increase the circulating βOHB concentration.

View Article and Find Full Text PDF

The acute response to therapeutic afterload reduction differs between heart failure with preserved (HFpEF) versus reduced ejection fraction (HFrEF), with larger left ventricular (LV) stroke work augmentation in HFrEF compared to HFpEF. This may (partially) explain the neutral effect of HFrEF-medication in HFpEF. It is unclear whether such differences in hemodynamic response persist and/or differentially trigger reverse remodeling in case of long-term afterload reduction.

View Article and Find Full Text PDF

Obesity, along with hypoxia, is known to be a risk factor for pulmonary hypertension (PH), which can lead to right ventricular hypertrophy and eventually heart failure. Both obesity and PH influence the autonomic nervous system (ANS), potentially aggravating changes in the right ventricle (RV). This study investigates the combined effects of obesity and hypoxia on the autonomic innervation of the RV in a mouse model.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!